Health Catalyst Inc

Health Catalyst Inc(HCAT)股票分析

$1.500

-0.085 (-5.66%)收盤時

Loading chart…
最高
1.590
開盤
1.590
成交量加權均價
1.51
成交量
336.35K
市值
357.16M
最低
1.450
成交金額
509.00K
企業價值/稅息折舊攤銷前利潤(TTM)
6.09

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.

AI 分析 of Health Catalyst Inc (HCAT)

賣出

Health Catalyst Inc is not a good buy right now. The current price is $1.58, which is significantly below the 52-week high of $3.36, indicating a decline of 53.0%. Additionally, the RSI is at 34.34, suggesting that the stock is oversold. The company has reported substantial losses, with a net income of -$111 million in Q1 2026 and -$40.5 million in Q2 2026, which raises concerns about its profitability. The main risk is the ongoing uncertainty around client churn and potential down-sell risks, as highlighted by analyst downgrades.

估值指標

Health Catalyst Inc(HCAT)目前預期本益比為 10.00,5 年平均預期本益比為 -7.88。

預期本益比

合理
5 年均值 P/E
-7.88
目前P/E
10.00
高估
103.22
低估
-118.99

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-53.03
目前EV/EBITDA
6.09
高估
98.36
低估
-204.42

預期股價營收比

合理
5 年均值 P/S
1.83
目前P/S
0.58
高估
3.43
低估
0.24

Alphio AI 對 HCAT 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%HCAT

$4.94

情境價格

基

基準

基準 · 50%HCAT

$4.25

情境價格

悲

悲觀

悲觀 · 25%HCAT

$4.22

情境價格

持有 HCAT 的大戶

F

First Light Asset Management, LLC

+ 持有HCAT

+0.00%

3個月報酬率

事件時間軸

2026-09-08 (ET)

09:00:00

Health Catalyst Appoints Simeon Kohl as CEO

2026-08-06 (ET)

17:30:00

Health Catalyst Closes Sale of Vitalware for $147 Million

17:00:00

Company Reports Q2 Revenue of $70.49M, Exceeding Expectations

17:00:00

Sees FY26 Adjusted EBITDA of $18M to $18.5M

17:00:00

Sees Q3 Adjusted EBITDA of $0-$500K

資訊

HCAT 常見問題 —— 由 Alphio AI 解答

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. It operates in the Technology sector (SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ET industry).

Health Catalyst Inc is not a good buy right now. The current price is $1.58, which is significantly below the 52-week high of $3.36, indicating a decline of 53.0%. Additionally, the RSI is at 34.34, suggesting that the stock is oversold. The company has reported substantial losses, with a net income of -$111 million in Q1 2026 and -$40.5 million in Q2 2026, which raises concerns about its profitability. The main risk is the ongoing uncertainty around client churn and potential down-sell risks, as highlighted by analyst downgrades.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易